Copyright
©The Author(s) 2023.
World J Clin Cases. Nov 16, 2023; 11(32): 7785-7794
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7785
Published online Nov 16, 2023. doi: 10.12998/wjcc.v11.i32.7785
Table 3 Etiology, treatment, and outcome of adult-onset hypophosphatemic osteomalacia
Etiology | Onset to diagnosis (mo) | ADV dose (mg/d) | ADV duration (yr) | Medication change | Time to symptom improvement (mo) | Time to normalization of phosphate (mo) | |
1 | Tumor-induced osteomalacia | 25 | N/A | N/A | N/A | 7 d | 2 d |
2 | ADV-induced nephropathy | 25 | 10 | 6 | Keep ADV | 3 | Never |
3 | ADV-induced nephropathy | 24 | 10 | 11 | Change to ETV | 0.5 | 3.5 |
4 | ADV-induced nephropathy | 6 | 10 | 10 | Discontinuation of ADV | 3 | 3 |
5 | ADV-induced nephropathy | 9 | Unknown | 11 | Change to ETV | 2 | 8 |
6 | Light-chain nephropathy due to multiple myeloma | 14 | N/A | N/A | N/A | 1 | Never |
7 | ADV-induced nephropathy | 27 | 10 | 4 | Change to ETV | 2 | 9 |
8 | ADV-induced nephropathy | 61 | 10 | 7 | Change to TAF | 1 | 1 |
- Citation: Kim S, Kim SW, Lee BC, Kim DH, Sung DH. Adult-onset hypophosphatemic osteomalacia as a cause of widespread musculoskeletal pain: A retrospective case series of single center experience. World J Clin Cases 2023; 11(32): 7785-7794
- URL: https://www.wjgnet.com/2307-8960/full/v11/i32/7785.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i32.7785